In a recent Twitter post, Elon Musk announced a significant milestone for his brain-computer interface company, Neuralink. According to Musk, the first human received an implant from Neuralink over the weekend, with the patient reportedly “recovering well.” The entrepreneur mentioned that the initial results showed promising neuron spike detection.
Although Musk did not provide details about the patient, Neuralink had previously expressed interest in recruiting individuals with quadriplegia or ALS for their trials.
The company, which aims to link the nervous system to computers, is part of a growing field with over 40 brain-computer interface trials currently underway, as per clinicaltrials.gov.
Neuralink’s device, about the size of a large coin, is designed for implantation in the skull, with ultra-thin wires directly entering the brain. The FDA had granted the company an “investigational device exemption,” allowing them to initiate clinical studies with eligible patients.
The September announcement from Neuralink outlined plans to place wires in a brain region controlling movement intention, with the initial goal of enabling users to control a computer cursor or keyboard using their thoughts.
Musk revealed in another post that the first Neuralink product, named “Telepathy,” aims to allow users to control phones or computers solely through thought, targeting those who have lost limb functionality.
However, the effectiveness and safety of such brain-computer interfaces remain uncertain. Clinical trials will play a crucial role in assessing these aspects and collecting data on the devices’ safety and efficacy over time.
Responding to Musk’s announcement, King’s College London professor Anne Vanhoestenberghe emphasised the need for time and more information to assess the success and safety of Neuralink’s procedure.
While acknowledging Neuralink’s entrance into a select group of companies with human implants, she stressed that true success should be measured in the long term, considering the stability of the interface over time and its actual benefits for participants.
Vanhoestenberghe expressed that there is currently insufficient information to evaluate the safety of the procedure.
